This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siddiqui, B. Articles by Hakomori, S.-i. Search for Related Content PubMed PubMed Citation Articles by Siddiqui, B. Articles by Hakomori, S.-i.

Change of Glycolipid Pattern in Morris Hepatomas 5123 and 7800¹

Biochemical Laboratory, Department of Pathobiology, University of Washington School of Public Health and Community Medicine, Seattle, Washington 98105

Glycolipids of three lines of Morris hepatomas (5123, 5123C, and 7800) were compared with those of neonatal and adult liver of rats (Buffalo strain). Ceramide with normal fatty acids; glucosylceramide; hematosides with N-glycolyl and N-acetylneuraminic acid; and mono-, di-, and trisialosyl gangliosides have been identified in normal and neonatal liver. The glycolipid patterns of normal adult and neonatal livers were similar and were characterized by the presence of trisialoganglioside and larger proportions of N-acetyl- and N-glycolyhematosides. Neonatal liver, however, contained a larger quantity of trisialoganglioside and a smaller quantity of monosialoganglioside than did normal liver. The patterns of these hepatomas resembled each other but were distinctively different from those of normal adult or neonatal livers. These tumor patterns were characterized by the absence of trisialoganglioside and a high level of disialoganglioside. A relative decrease of the level of hematosides and an increase of neutral glycolipids and ceramide were also observed. The principle of these pattern changes was identical to that of previous observations in cultured cells and their viral transformants, namely deletion of nonreducing terminal glycolipids and simultaneous increase of precursor glycolipids.

¹ This work was supported by American Cancer Society Research Grant T-475 and USPHS Research Grant CA-10909. This is the third report on "glycolipid in malignancy." A preliminary note of a part of this investigation was published (28).

² To whom communications should be addressed.

Received 5/14/70. Accepted 8/12/70.

This article has been cited by other articles:

				M. L. Allende, J. Li, D. S. Darling, C. A. Worth, and W. W. Young Jr. Evidence supporting a late Golgi location for lactosylceramide to ganglioside GM3 conversion Glycobiology, October 1, 2000; 10(10): 1025 - 1032. [Abstract] [Full Text] [PDF]

				A. E. Stapleton, M. R. Stroud, S. I. Hakomori, and W. E. Stamm The Globoseries Glycosphingolipid Sialosyl Galactosyl Globoside Is Found in Urinary Tract Tissues and Is a Preferred Binding Receptor In Vitro for Uropathogenic Escherichia coli Expressing pap-Encoded Adhesins Infect. Immun., August 1, 1998; 66(8): 3856 - 3861. [Abstract] [Full Text] [PDF]

				W. Young Jr and S. Hakomori Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo Science, January 30, 1981; 211(4481): 487 - 489. [Abstract] [PDF]

				P. Fishman and R. Brady Biosynthesis and function of gangliosides Science, November 26, 1976; 194(4268): 906 - 915. [Abstract] [PDF]